- Home
- DVAX vs AHCO Comparison
DVAX vs AHCO Comparison
Compare DVAX & AHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- AHCO
- Stock Information
- Founded
- DVAX 1996
- AHCO 2012
- Country
- DVAX United States
- AHCO United States
- Employees
- DVAX N/A
- AHCO N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- AHCO Medical/Nursing Services
- Sector
- DVAX Health Care
- AHCO Health Care
- Exchange
- DVAX Nasdaq
- AHCO Nasdaq
- Market Cap
- DVAX 1.2B
- AHCO 1.3B
- IPO Year
- DVAX 2004
- AHCO N/A
- Fundamental
- Price
- DVAX $11.21
- AHCO $9.41
- Analyst Decision
- DVAX Buy
- AHCO Strong Buy
- Analyst Count
- DVAX 4
- AHCO 5
- Target Price
- DVAX $26.50
- AHCO $13.60
- AVG Volume (30 Days)
- DVAX 1.7M
- AHCO 1.1M
- Earning Date
- DVAX 11-05-2025
- AHCO 11-04-2025
- Dividend Yield
- DVAX N/A
- AHCO N/A
- EPS Growth
- DVAX N/A
- AHCO N/A
- EPS
- DVAX N/A
- AHCO 0.55
- Revenue
- DVAX $330,514,000.00
- AHCO $3,255,213,000.00
- Revenue This Year
- DVAX $23.23
- AHCO $0.89
- Revenue Next Year
- DVAX $16.57
- AHCO $6.84
- P/E Ratio
- DVAX N/A
- AHCO $16.78
- Revenue Growth
- DVAX 26.73
- AHCO N/A
- 52 Week Low
- DVAX $9.20
- AHCO $7.11
- 52 Week High
- DVAX $14.63
- AHCO $11.63
- Technical
- Relative Strength Index (RSI)
- DVAX 64.07
- AHCO 51.98
- Support Level
- DVAX $10.97
- AHCO $9.33
- Resistance Level
- DVAX $11.43
- AHCO $9.81
- Average True Range (ATR)
- DVAX 0.36
- AHCO 0.45
- MACD
- DVAX 0.07
- AHCO -0.04
- Stochastic Oscillator
- DVAX 86.42
- AHCO 36.93
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About AHCO AdaptHealth Corp.
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.